硼替卡德 2.5mg 注射液

What is Bortezomib 2.5mg Injection?

Bortezomib 2.5mg Injection is a targeted therapy medication used to treat certain types of cancer, primarily multiple myeloma and mantle cell lymphoma. It belongs to a class of drugs known as proteasome inhibitors.

Active Ingredient and How it Works:

The active ingredient is Bortezomib. Bortezomib works by inhibiting the proteasome, a complex of proteins within cells that breaks down unwanted or damaged proteins. In cancer cells, particularly myeloma cells, the proteasome plays a crucial role in their survival and proliferation. By blocking the proteasome, Bortezomib causes an accumulation of abnormal proteins within the cancer cells, leading to cell stress and ultimately triggering programmed cell death (apoptosis).

Indications:

• Multiple Myeloma: Used in patients who have received at least one prior therapy, or as initial therapy in combination with other chemotherapy agents.
• Mantle Cell Lymphoma: Used in patients with relapsed or refractory mantle cell lymphoma.

Dosage and Administration:

The dosage and administration of Bortezomib 2.5mg Injection should be strictly determined by a qualified healthcare professional. It is typically administered subcutaneously or intravenously. The frequency and duration of treatment depend on the specific cancer type, stage, and individual patient response.

Side Effects:

Common side effects may include fatigue, nausea, diarrhea, constipation, loss of appetite, peripheral neuropathy (numbness, tingling, or pain in hands and feet), and thrombocytopenia (low platelet count). Serious side effects can also occur, and patients should report any unusual symptoms to their doctor immediately.

Storage:

Unused vials should be stored at room temperature, protected from light. Once reconstituted, the solution should be used promptly. Consult your pharmacist or doctor for specific storage instructions.